In contrast, loss or antagonism of LAIR1 signaling using LAIR1 KO, an anti-LAIR1 antagonist antibody, or a fusion of two LAIR2 molecules to an IgG1 backbone combined with checkpoint and, in some cases TGF-β blockade, has been shown to result in reduced tumor growth, increased infiltration of cytotoxic T cells, and remodeling of the extracellular matrix in models of solid tumors (breast, colon, lung) (18–21). The gene discussed is LAIR1; the disease is neoplasm.